Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.19.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Total revenue $ 3,618 $ 6,752 $ 16,073 $ 8,601
Operating expenses:        
Research and development 15,249 8,290 33,946 22,640
General and administrative 4,509 3,538 14,049 10,165
Loss on impairment of in-process research and development 22,123 0 22,123 0
Total operating expenses 41,881 11,828 70,118 32,805
Loss from operations 38,263 5,076 54,045 24,204
Interest and other income, net 396 107 1,449 307
Interest and other expense, net (353) (279) (947) (672)
Change in fair value of warrant liabilities 1 4 3 916
Net loss attributable to common shareholders $ 38,219 $ 5,244 $ 53,540 $ 23,653
Net loss per share attributable to common shareholders:        
Basic and diluted $ 1.03 $ 0.19 $ 1.45 $ 0.87
Weighted average number of shares used in net loss per share calculations:        
Basic and diluted 36,937,912 27,680,307 36,832,966 27,246,667
Research And Development Revenue | Other        
Total revenue $ 284 $ 117 $ 284 $ 197
Research And Development Revenue | Related Party        
Total revenue 2,903 1,914 14,527 3,009
Grant        
Total revenue $ 431 $ 4,721 $ 1,262 $ 5,395